F. Lefevreborg et al., ALFUZOSIN, A SELECTIVE ALPHA-1-ADRENOCEPTOR ANTAGONIST IN THE LOWER URINARY-TRACT, British Journal of Pharmacology, 109(4), 1993, pp. 1282-1289
1 Phenylephrine-induced contractions of rabbit isolated trigone and ur
ethra were antagonized in a competitive manner by alfuzosin (pA2 7.44
and 7.30, respectively) and prazosin. 2 The characteristics of [H-3]-p
razosin binding to human prostatic adenoma tissue were evaluated. [H-3
]-prazosin was potently displaced by alpha1-adrenoceptor specific agen
ts including alfuzosin, its (+)- and (-)-enantiomers and prazosin (IC5
0 0.035, 0.023, 0.019 and 0.004 mum, respectively), but only weakly by
alpha2-adrenoceptor selective agents, for example, yohimbine (IC50= 6
.0 muM).3 In the pithed rat, alfuzosin (0.03-0.3 mg kg-1, i.v.) marked
ly inhibited pressor responses produced by the alpha1-selective agonis
t, cirazoline but inhibited only slightly responses to the alpha2-sele
ctive agonist, UK 14,304. Alfuzosin (I mg kg-1, i.v.) had minimal effe
cts against responses mediated by stimulation of prejunctional alpha2-
receptors (UK 14,304-induced inhibition of sympathetic tachycardia). 4
In the anaesthetized cat, alfuzosin (0.001-1 mg kg-1, i.v.) and prazo
sin (0.001-0.3 mg kg-1, i.v.) produced dose-related inhibition of the
increases in urethral pressure caused by stimulation of sympathetic hy
pogastric nerves. Prazosin was approximately 5 fold more potent than a
lfuzosin. When phenylephrine was employed to induce urethral and vascu
lar alpha1-mediated tone simultaneously, prazosin inhibited both stimu
li with similar potency whereas alfusozin was 3-5 fold more potent aga
inst elevated urethral pressure. This functional uroselectivity of alf
uzosin was more evident by the intraduodenal route, since doses of 0.0
3 and 0.1 mg kg-1 alfuzosin inhibited urethral pressure with minimal e
ffects on arterial blood pressure. 5 Alfuzosin is a potent selective a
lpha1-adrenoceptor antagonist in tissues of the lower urinary tract in
cluding the human prostate. This provides a pharmacological basis for
its use in the treatment of benign prostatic hypertrophy.